我武生物(300357) - 2018 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2018 was ¥500,744,692.07, representing a 29.87% increase compared to ¥385,576,841.66 in 2017[22] - The net profit attributable to shareholders for 2018 was ¥232,884,097.51, a 25.14% increase from ¥186,103,945.40 in 2017[22] - The net profit after deducting non-recurring gains and losses was ¥224,864,128.66, up 27.33% from ¥176,604,724.34 in 2017[22] - The net cash flow from operating activities was ¥206,452,525.31, reflecting a 29.73% increase compared to ¥159,134,139.23 in 2017[22] - The total assets at the end of 2018 were ¥1,057,892,508.68, a 24.71% increase from ¥848,311,200.92 at the end of 2017[22] - The net assets attributable to shareholders at the end of 2018 were ¥969,517,290.46, which is a 21.00% increase from ¥801,257,929.88 at the end of 2017[22] - The basic earnings per share for 2018 was ¥0.8006, up 25.13% from ¥0.6398 in 2017[22] - The diluted earnings per share for 2018 was also ¥0.8006, reflecting the same 25.13% increase from ¥0.6398 in 2017[22] - The weighted average return on equity for 2018 was 26.63%, an increase of 1.08% from 25.55% in 2017[22] Research and Development - The company invested 38.62 million yuan in R&D, accounting for 7.71% of operating revenue[42] - The company holds 13 valid domestic invention patents and several international patents, indicating strong R&D capabilities[42] - Research and development expenses rose to CNY 134.79 million, a significant increase of 75.01% due to new stem cell research projects[47] - The company is actively expanding its product line in the allergy treatment sector, with several products in various stages of clinical trials[51] Product and Market Performance - The company’s main product, the dust mite drop, maintains the highest market share in the dust mite desensitization drug market since 2012[41] - Revenue from pharmaceutical manufacturing was ¥498,413,975.94, accounting for 99.53% of total revenue, with a year-on-year growth of 30.50%[55] - The sales volume of dust mite drops increased by 31.82% year-on-year, with production volume rising by 45.51% and inventory volume by 54.69%[61] - The company’s gross profit margin for pharmaceutical manufacturing was 94.62%, with a year-on-year increase of 30.50%[60] Cash Flow and Investments - Cash and cash equivalents rose to 274.23 million yuan, an increase of 147.58% primarily from the redemption of bank wealth management products[40] - The company's cash flow from investment activities turned positive with a net inflow of ¥132,391,291.78, a significant improvement from a net outflow in the previous year[75] - The net increase in cash and cash equivalents surged by 652.22% to ¥274,228,878.88, attributed to higher cash flows from both investment and operating activities[75] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of ¥2.50 per 10 shares and issue 8 bonus shares for every 10 shares held[6] - The cash dividend represents 31.23% of the net profit attributable to ordinary shareholders for 2018, which was RMB 232,884,097.51[113] - The proposed profit distribution plan is subject to approval at the 2018 annual shareholders' meeting[111] Corporate Governance and Compliance - The company has committed to not transferring or entrusting the management of its shares for 36 months post-IPO, with a maximum annual transfer of 25% of total shares held during the tenure of the individual or their affiliates[116] - The company has maintained compliance with commitments regarding avoiding competition and related transactions during the reporting period[116] - The company has made commitments regarding the accuracy and completeness of its prospectus, ensuring investor protection against losses due to false statements or omissions[121] Subsidiaries and Corporate Structure - The company established Shanghai Iwu Stem Cell Technology Co., Ltd. with an investment of 30 million RMB[165] - The company has established three new subsidiaries in 2018, including Shanghai Iwu Stem Cell Technology Co., Ltd. with a registered capital of RMB 15 million and Zhejiang Iwu Stem Cell Technology Co., Ltd. with RMB 3 million[135] - The company has canceled its subsidiary WOLWOPHARMA (MALAYSIA) SDN.BHD., which was involved in the import, manufacturing, and retail of pharmaceuticals, effective June 2018[134] Management and Shareholding - The actual controller of the company is Hu Gengxi, who is also the chairman and general manager[185] - The company has a diverse board with members holding advanced degrees and extensive experience in biotechnology and finance[196][198] - The total number of shares held by the board members, supervisors, and senior management at the beginning of the period were 24,451,494 shares, which increased to 43,764,309 shares by the end of the period, reflecting a net increase of 19,561,195 shares[192]